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Chlebowski et al.1 showed the results of the Women’s 
Health Initiative (WHI) regarding the risk of breast can-
cer in women who used bisphosphonates. Thus, in an 
observational study with 154,768 patients, 2816 of whom 
used oral bisphosphonates (90% alendronate and 10% eti-
dronate), they observed that, after 7.8 years of follow-up, 
the incidence of invasive breast cancer was lower in pa-
tients who used bisphosphonates (hazard ratio [HR], 0.68, 
95%CI, 0.52-0.88; p < 0.01). When they performed seg-
mented analysis of the data, they observed that the effects 
of the drug was observed both in patients with estrogen 
receptor (ER)-positive breast cancer, where a reduction of 
the incidence reached a HR of 0.70 (95%CI, 0.52-0.94; p 
< 0.02), and ER-negative patients, although the results in 
the last group were not statistically significant, probably 
due to the low number of women in this group (HR, 0.66, 
95%CI, 0.31-1.39; p < 0.27). Gad Rennert et al.2, observed 
that the use of bisphosphonates for at least 1 year before 
the diagnosis of breast cancer was associated with a sig-
nificant reduction in the risk of breast cancer (Odds Ratio 
[OR] 0.61; 95%CI, 0.50-0.76), which remained significant 
after adjusting them for variables, such as age, ingestion 
of fruits and vegetables, physical activity, family history of 
breast cancer, ethnic group, body mass index, use of cal-
cium supplements/hormone replacement therapy, number 
of pregnancies, breast feeding, and age of first pregnancy 
(OR, o.72; 95%CI, 0.57-0.90). Besides, ER-positive and 
well differentiated tumors were observed more often in 
patients treated with bisphosphonates.
COMMENTS
Bisphosphonates are commonly used for prevention and 
treatment of osteopenia and osteoporosis, but they also 
to reduce bone metastasis-related bone fractures. Besides, 
studies with patients using oral and intravenous bisphos-
phonates also demonstrated the possibility of reducing lo-
coregional recurrence of breast cancer3.
Studies have evaluated the influence of the adjuvant 
use of clodronate on recurrence of breast cancer. In the 
study with the greatest cohort, placebo-controlled and 
randomized study, patients who used 1600 mg/day of clo-
dronate showed a significant reduction in bone metastasis 
and greater overall survival4.
Gnant et al.5 have demonstrated that the association of 
zoledronic acid to the endocrine therapy of patients with 
premenopausal ER-positive breast cancer determine longer 
disease-free survival when compared to the group of pa-
tients who did not use this association. They also observed 
six cases of contralateral breast cancer in the group of 899 
patients who were on zoledronic acid against 10 cases in the 
group of 904 patients who did not. Thus, they hypothesized 
that this drug might have chemoprotective properties, since 
it reduced the incidence of contralateral breast cancer in-
stead of simply suppressing metastasis.
In the conjoined analysis of the ZFAST (Zometa-Femara 
Adjuvant Synergy Trial) ZOFAST (Zoledronic acid in the 
Prevention of Cancer Treatment-Induced Bone Loss in 
Postmenopausal Women Receiving Letrozole as Adjuvant 
Therapy for Early Breast Cancer) trials, 35% reduction in 
disease recurrence was observed (p = 0.04)6 in postmeno-
pausal patients with breast cancer treated with 4 mg of in-
travenous zoledronic acid every six months. In the AZURE 
trial (Adjuvan Zoledronic acid to RedUce Recurrence), the 
use of zoledronic acid as a neoadjuvant doubled the remis-
sion rate of the disease7. Those results suggest that the direct 
inhibitory effect against breast cancer could be the mecha-
nism involved.
Corroborating the studies of Chlebowski et al.1 and 
Gad Rennert et al.2, Newcomb et al.8, in the University of 
Wisconsin, observed, through case-controlled studies with 
a 3-year follow-up in 2936 breast cancer patients and 2975 
patients without the disease, that the use of bisphosphonates 
was a reducing factor in the risk of breast cancer in non-
obese patients, with HR of 0.67 (95%CI, 0.51-0.89, p = 0.01).
In vivo studies using animal models with breast can-
cer-induced bone disease have demonstrated that bisphos-
phonates have anti-tumor effects through inhibition of 
osteolysis and reducing bone disease. Besides, preclinical 
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studies have demonstrated and synergic anti-tumor effect 
between commonly used chemotherapy agents used in the 
treatment of breast cancer and bisphosphonates10.
The mechanisms by which bisphosphonates can re-
duce the incidence of breast cancer are not known. Based 
on preclinical studies, it has been hypothesized that this 
drug can affect angiogenesis by reducing VEGF, therefore 
inducing apoptosis, besides reducing the proliferation and 
prevent invasion of the extracellular matrix9. Those mech-
anisms differ from those involved in the action of selective 
estrogen receptors modulators (SERMs), where protection 
is seen exclusively in ER-positive breast cancer11, while 
with bisphosphonates, protection is seen also in ER-nega-
tive breast cancer, corresponding to 30% of breast cancers.
Despite those data justifying a possible chemopreven-
tive action of bisphosphonates in breast cancer, it is pre-
mature to use it in the prevention of this disease. Further 
randomized studies are necessary to test their real e cacy 
in clinical use.
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